SEPTInvestingStart Free
Stocks/DRTS/SEC Filings/6-K Nov 16, 2026

DRTS 6-K: SEC filing

Alpha Tau Medical

Filed with the SEC on Nov 16, 2026 · accession 0001213900-26-120072

DRTS filed a 6-K (foreign company report) with the SEC on Nov 16, 2026. How foreign companies listed in the US report news and events — like an 8-K for them.

Summary of the filing

Alpha Tau Medical announced positive interim results from its U.S. Alpha DaRT recurrent glioblastoma trial, reporting that all treated patients are alive with median survival not reached, 100% objective response rate, and no unanticipated serious adverse events in the first six evaluable patients.

For details, click here →How to read a 6-K →

Key details

RegistrantAlpha Tau Medical Ltd.
Chief executive officerUzi Sofer

✦ Ask GOAX AI about this filing — what it means for DRTS, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for DRTS?

Click here

Frequently asked questions

What did DRTS file with the SEC on Nov 16, 2026?

DRTS filed a 6-K (SEC filing). Alpha Tau Medical announced positive interim results from its U.S. Alpha DaRT recurrent glioblastoma trial, reporting that all treated patients are alive with median survival not reached, 100% objective response rate, and no unanticipated serious adverse events in the first six evaluable patients.

How do I read a 6-K?

How foreign companies listed in the US report news and events — like an 8-K for them. Look at the exhibit names: "results", "resign", "notice" tell you the topic. Many 6-Ks are routine (meeting notices); results and leadership changes matter most.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 6-K (foreign company report): How foreign companies listed in the US report news and events — like an 8-K for them.

Other DRTS SEC filings

  • 6-K · SEC filingNov 12, 2026
  • 6-K · SEC filingOct 29, 2026
  • 6-K · Material agreementOct 22, 2026
  • 6-K · Fda approvalOct 19, 2026
  • 6-K · Fda approvalAug 31, 2026
  • 6-K · SEC filingAug 10, 2026
  • 6-K · SEC filingAug 10, 2026
  • 6-K · Fda approvalJul 21, 2026
  • 6-K · Fda approvalJul 15, 2026
  • 144 · Insider sale plannedJul 6, 2026

Get alerts when DRTS files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
DRTS overviewDRTS analysisDRTS newsLatest SEC filings
Source: SEC EDGAR filing 0001213900-26-120072. The summary and key details are extracted by SEPT from the filing and may contain errors. Price reaction uses daily closing prices. Not financial advice.